title: At the Crossroads of Cancer Stem Cells, Radiation Biology, and Radiation Oncology.
abstract: Reports that a small subset of tumor cells initiate and sustain tumor growth, are resistant to radiation and drugs, and bear specific markers have led to an explosion of cancer stem cell research. These reports imply that the evaluation of therapeutic response by changes in tumor volume is misleading, as volume changes reflect the response of the sensitive rather than the resistant tumorigenic cell population. The reports further suggest that the marker-based selection of the tumor cell population will facilitate the development of radiation treatment schedules, sensitizers, and drugs that specifically target the resistant tumorigenic cells that give rise to treatment failure. This review presents evidence that contests the observations that cancer stem cell markers reliably identify the subset of tumor cells that sustain tumor growth and that the marker-identified population is radioresistant relative to the marker-negative cells. Experimental studies show that cells and tumors that survive large radiation doses are not more radioresistant than unirradiated cells and tumors, and also show that the intrinsic radiosensitivity of unsorted colony-forming tumor cells, in combination with the fraction of unsorted tumor cells that are tumor initiating, predicts tumor radiocurability.
authors.affiliation: Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. lgerweck@partners.org.
authors.forename: Leo E
authors.initials: LE
authors.lastname: Gerweck
authors.affiliation: Brain Tumor Research Center, Massachusetts General Hospital, Boston, Massachusetts.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Wakimoto
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D014411:Neoplastic Stem Cells / Q000528:radiation effects*; D011836:Radiation Tolerance; D011853:Radiobiology; D011879:Radiotherapy Dosage